Gilead Hit With Class Action Suit Over HIV Treatments

January 27, 2020

Health insurers filed a class action suit against Gilead in a Florida federal court accusing it of anticompetitive behavior over its HIV treatments.

The insurers accused the drugmaker of blocking generic entry of its HIV treatments by entering into anticompetitive agreements and of changing a formulation just before patents on its product expired in 2018.

The complaint in the U.S. District Court for the Southern District of Florida alleges that Gilead entered deals with generic competitors to prevent them from marketing generic versions of tenofovir disoproxil (TDF) even after the patent on the drug expired.

View today's stories